Similar articles for PMID: 24231949

Year	Number of Results
2005	2
2006	6
2007	6
2008	5
2009	10
2010	14
2011	20
2012	10
2013	9
2014	6
2015	2
2016	6
2017	4
2018	4
2019	2
2020	5
2021	3
2022	1
2024	0

1

p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy.

Rao B, Lain S, Thompson AM. Rao B, et al. Br J Cancer. 2013 Dec 10;109(12):2954-8. doi: 10.1038/bjc.2013.702. Epub 2013 Nov 14. Br J Cancer. 2013. PMID: 24231949 Free PMC article. Review.

2

An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells.

van Leeuwen IM, Rao B, Sachweh MC, Laín S. van Leeuwen IM, et al. Cell Cycle. 2012 May 1;11(9):1851-61. doi: 10.4161/cc.20254. Epub 2012 May 1. Cell Cycle. 2012. PMID: 22517433 Free PMC article.

3

Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.

Rao B, van Leeuwen IM, Higgins M, Campbel J, Thompson AM, Lane DP, Lain S. Rao B, et al. Oncotarget. 2010 Nov;1(7):639-50. doi: 10.18632/oncotarget.101015. Oncotarget. 2010. PMID: 21317459 Free PMC article.

4

Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy.

Choong ML, Yang H, Lee MA, Lane DP. Choong ML, et al. Cell Cycle. 2009 Sep 1;8(17):2810-8. doi: 10.4161/cc.8.17.9503. Epub 2009 Sep 13. Cell Cycle. 2009. PMID: 19657224

5

Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.

Miyachi M, Kakazu N, Yagyu S, Katsumi Y, Tsubai-Shimizu S, Kikuchi K, Tsuchiya K, Iehara T, Hosoi H. Miyachi M, et al. Clin Cancer Res. 2009 Jun 15;15(12):4077-84. doi: 10.1158/1078-0432.CCR-08-2955. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509161

6

Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.

Cheok CF, Dey A, Lane DP. Cheok CF, et al. Mol Cancer Res. 2007 Nov;5(11):1133-45. doi: 10.1158/1541-7786.MCR-07-0161. Mol Cancer Res. 2007. PMID: 18025259

7

Mechanism-specific signatures for small-molecule p53 activators.

van Leeuwen IM, Higgins M, Campbell J, Brown CJ, McCarthy AR, Pirrie L, Westwood NJ, Laín S. van Leeuwen IM, et al. Cell Cycle. 2011 May 15;10(10):1590-8. doi: 10.4161/cc.10.10.15519. Epub 2011 May 15. Cell Cycle. 2011. PMID: 21490429

8

Recent advances in the therapeutic perspectives of Nutlin-3.

Secchiero P, Bosco R, Celeghini C, Zauli G. Secchiero P, et al. Curr Pharm Des. 2011;17(6):569-77. doi: 10.2174/138161211795222586. Curr Pharm Des. 2011. PMID: 21391907 Review.

9

P53 activation suppresses irinotecan metabolite SN-38-induced cell damage in non-malignant but not malignant epithelial colonic cells.

Gunasegaran B, Neilsen PM, Smid SD. Gunasegaran B, et al. Toxicol In Vitro. 2020 Sep;67:104908. doi: 10.1016/j.tiv.2020.104908. Epub 2020 Jun 2. Toxicol In Vitro. 2020. PMID: 32502622

10

The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.

Deben C, Wouters A, Op de Beeck K, van Den Bossche J, Jacobs J, Zwaenepoel K, Peeters M, Van Meerbeeck J, Lardon F, Rolfo C, Deschoolmeester V, Pauwels P. Deben C, et al. Oncotarget. 2015 Sep 8;6(26):22666-79. doi: 10.18632/oncotarget.4433. Oncotarget. 2015. PMID: 26125230 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

98 results

Results by year